Pharmacokinetics and Dosing of Anti-infective Drugs in Patients on Extracorporeal Membrane Oxygenation: A Review of the Current Literature

Clinical Therapeutics

Volumn 38, Issue 9, 2016, Pages 1976-1994

  Sherwin, Jennifer ^a   Heath, Travis ^a   Watt, Kevin ^a  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

anti infectives; antibiotics; antifungals; antivirals; ECMO; pharmacokinetics

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANTIINFECTIVE AGENT; AZITHROMYCIN; CASPOFUNGIN; CEFOTAXIME; ETHAMBUTOL; FLUCONAZOLE; GANCICLOVIR; GENTAMICIN; IMIPENEM; LINEZOLID; MEROPENEM; MICAFUNGIN; OSELTAMIVIR; PERAMIVIR; PIPERACILLIN PLUS TAZOBACTAM; PYRAZINAMIDE; RIBAVIRIN; RIFAMPICIN; TIGECYCLINE; VANCOMYCIN; VORICONAZOLE; ANTIFUNGAL AGENT; ANTIVIRUS AGENT;

BIBLIOGRAPHIC DATABASE; BLOOD VOLUME; COMPARATIVE STUDY; CONTROLLED STUDY; CRITICALLY ILL PATIENT; DRUG ADSORPTION; DRUG CLEARANCE; DRUG DEGRADATION; DRUG ISOLATION; DRUG MECHANISM; DRUG MONITORING; EXTRACORPOREAL OXYGENATION; HEMODILUTION; HUMAN; NONHUMAN; PHYSICAL CHEMISTRY; PROTEIN BINDING; REVIEW; VOLUME OF DISTRIBUTION; ADVERSE EFFECTS; CRITICAL ILLNESS; DRUG ADMINISTRATION;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; ANTIFUNGAL AGENTS; ANTIVIRAL AGENTS; CRITICAL ILLNESS; DRUG ADMINISTRATION SCHEDULE; EXTRACORPOREAL MEMBRANE OXYGENATION; HUMANS;

EID: 84988644109     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2016.07.169     Document Type: Review

References (86)

1. 1 Bhatt-Mehta V, Johnson CE, Schumacher RE2, Gentamicin pharmacokinetics in term neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 12 (1992), 28–32.
2. 2 Dagan, O., Klein, J., Gruenwald, C., et al. Preliminary studies of the effects of extracorporeal membrane oxygenator on the disposition of common pediatric drugs. Ther Drug Monit 15 (1993), 263–266.
3. 3 Harthan, A.A., Buckley, K.W., Heger, M.L., et al. Medication adsorption into contemporary extracorporeal membrane oxygenator circuits. J Pediatr Pharmacol Ther 19 (2014), 288–295.
4. 4 Koren, G., Crean, P., Klein, J., et al. Sequestration of fentanyl by the cardiopulmonary bypass (CPBP). Eur J Clin Pharmacol 27 (1984), 51–56.
5. 5 Lemaitre, F., Hasni, N., Leprince, P., et al. Propofol, midazolam, vancomycin and cyclosporine therapeutic drug monitoring in extracorporeal membrane oxygenation circuits primed with whole human blood. Crit Care, 19, 2015, 40.
6. 6 Mehta, N.M., Halwick, D.R., Dodson, B.L., et al. Potential drug sequestration during extracorporeal membrane oxygenation: results from an ex vivo experiment. Intensive Care Med 33 (2007), 1018–1024.
7. 7 Mulla, H., Lawson, G., von Anrep, C., et al. In vitro evaluation of sedative drug losses during extracorporeal membrane oxygenation. Perfusion 15 (2000), 21–26.
8. 8 Shekar, K., Roberts, J.A., McDonald, C.I., et al. Sequestration of drugs in the circuit may lead to therapeutic failure during extracorporeal membrane oxygenation. Crit Care, 16, 2012, R194.
9. 9 Shekar, K., Roberts, J.A., McDonald, C.I., et al. Protein-bound drugs are prone to sequestration in the extracorporeal membrane oxygenation circuit: results from an ex vivo study. Crit Care, 19, 2015, 164.
10. 10 Wildschut, E.D., Ahsman, M.J., Allegaert, K., et al. Determinants of drug absorption in different ECMO circuits. Intensive Care Med 36 (2010), 2109–2116.
11. 11 Preston, T.J., Hodge, A.B., Riley, J.B., et al. In vitro drug adsorption and plasma free hemoglobin levels associated with hollow fiber oxygenators in the extracorporeal life support (ECLS) circuit. J Extra Corpor Technol 39 (2007), 234–237.
12. 12 Preston, T.J., Ratliff, T.M., Gomez, D., et al. Modified surface coatings and their effect on drug adsorption within the extracorporeal life support circuit. J Extra Corpor Technol 42 (2010), 199–202.
13. 13 Palmgren, J.J., Monkkonen, J., Korjamo, T., et al. Drug adsorption to plastic containers and retention of drugs in cultured cells under in vitro conditions. Eur J Pharm Biopharm 64 (2006), 369–378.
14. 14 Unger, J.K., Kuehlein, G., Schroers, A., et al. Adsorption of xenobiotics to plastic tubing incorporated into dynamic in vitro systems used in pharmacological research–limits and progress. Biomaterials 22 (2001), 2031–2037.
15. 15 De Somer, F., Francois, K., van Oeveren, W., et al. Phosphorylcholine coating of extracorporeal circuits provides natural protection against blood activation by the material surface. Eur J Cardiothorac Surg 18 (2000), 602–606.
16. 16 Palatianos, G.M., Foroulis, C.N., Vassili, M.I., et al. A prospective, double-blind study on the efficacy of the bioline surface-heparinized extracorporeal perfusion circuit. Ann Thorac Surg 76 (2003), 129–135.
17. 17 Tayama, E., Hayashida, N., Akasu, K., et al. Biocompatibility of heparin-coated extracorporeal bypass circuits: new heparin bonded bioline system. Artif Organs 24 (2000), 618–623.
18. 18 Buck, M.L., Pharmacokinetic changes during extracorporeal membrane oxygenation: implications for drug therapy of neonates. Clin Pharmacokinet 42 (2003), 403–417.
19. 19 Butler, J., Pathi, V.L., Paton, R.D., et al. Acute-phase responses to cardiopulmonary bypass in children weighing less than 10 kilograms. Ann Thorac Surg 62 (1996), 538–542.
20. 20 Kozik, D.J., Tweddell, J.S., Characterizing the inflammatory response to cardiopulmonary bypass in children. Ann Thorac Surg 81 (2006), S2347–S2354.
21. 21 McIlwain, R.B., Timpa, J.G., Kurundkar, A.R., et al. Plasma concentrations of inflammatory cytokines rise rapidly during ECMO-related SIRS due to the release of preformed stores in the intestine. Lab Invest 90 (2010), 128–139.
22. 22 Seghaye, M.C., Grabitz, R.G., Duchateau, J., et al. Inflammatory reaction and capillary leak syndrome related to cardiopulmonary bypass in neonates undergoing cardiac operations. J Thorac Cardiovasc Surg 112 (1996), 687–697.
23. 23 Anderson, H.L. 3rd, AACoran, A.G., Drongowski, R.A., et al. Extracellular fluid and total body water changes in neonates undergoing extracorporeal membrane oxygenation. J Pediatr Surg 27 (1992), 1003–1007 discussion 1007-1008.
24. 24 Many, M., Soroff, H.S., Birtwell, W.C., et al. The physiologic role of pulsatile and nonpulsatile blood flow. II. Effects on renal function. Arch Surg 95 (1967), 762–767.
25. 25 Ehrnebo, M., Agurell, S., Jalling, B., et al. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol 3 (1971), 189–193.
26. 26 Friis-Hansen, B., Water distribution in the foetus and newborn infant. Acta Paediatr Scand Suppl 305 (1983), 7–11.
27. 27 McNamara, P.J., Alcorn, J., Protein binding predictions in infants. AAPS PharmSci, 4, 2002, E4.
28. 28 Extracorporeal Life Support Organization. ECLS Registry Report: International Summary. 2016; https://www.elso.org/Registry/Statistics/InternationalSummary.aspx.
29. 29 Mulla, H., Lawson, G., Firmin, R., et al. Drug Disposition During Extracorporeal Membrane Oxygenation (ECMO). Pediatric and Perinatal Drug Therapy 4 (2001), 109–120.
30. 30 Morgan, E.T., Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev 29 (1997), 1129–1188.
31. 31 Abdel-Razzak, Z., Loyer, P., Fautrel, A., et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 44 (1993), 707–715.
32. 32 Rivory, L.P., Slaviero, K.A., Clarke, S.J., Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 87 (2002), 277–280.
33. 33 Siewert, E., Bort, R., Kluge, R., et al. Hepatic cytochrome P450 down-regulation during aseptic inflammation in the mouse is interleukin 6 dependent. Hepatology 32 (2000), 49–55.
34. 34 Richardson, T.A., Sherman, M., Kalman, D., et al. Expression of UDP-glucuronosyl transferase isoform mRNAs during inflammation and infection in mouse liver and kidney. Drug Metab Dispos 34 (2006), 351–353.
35. 35 Bizzarro, M.J., Conrad, S.A., Kaufman, D.A., et al. Extracorporeal Life Support Organization Task Force on Infections EMO. Infections acquired during extracorporeal membrane oxygenation in neonates, children, and adults. Pediatr Crit Care Med 12 (2011), 277–281.
36. 36 Extracorporeal Life Support Organization Registry Report: International Summary. January 2016. https://www.elso.org/. Accessed February 29, 2016.
37. 37 Amaker, R.D., DiPiro, J.T., Bhatia, J., Pharmacokinetics of vancomycin in critically ill infants undergoing extracorporeal membrane oxygenation. Antimicrob Agents Chemother 40 (1996), 1139–1142.
38. 38 Buck, M.L., Vancomycin pharmacokinetics in neonates receiving extracorporeal membrane oxygenation. Pharmacotherapy 18 (1998), 1082–1086.
39. 39 Mulla, H., Pooboni, S., Population pharmacokinetics of vancomycin in patients receiving extracorporeal membrane oxygenation. Br J Clin Pharmacol 60 (2005), 265–275.
40. 40 Hoie, E.B., Swigart, S.A., Leuschen, M.P., et al. Vancomycin pharmacokinetics in infants undergoing extracorporeal membrane oxygenation. Clin Pharm 9 (1990), 711–715.
41. 41 Donadello, K., Roberts, J.A., Cristallini, S., et al. Vancomycin population pharmacokinetics during extracorporeal membrane oxygenation therapy: a matched cohort study. Crit Care, 18, 2014, 632.
42. 42 Park, S.J., Yang, J.H., Park, H.J., et al. Trough Concentrations of Vancomycin in Patients Undergoing Extracorporeal Membrane Oxygenation. PLoS One, 10, 2015, e0141016.
43. 43 Wu, C.C., Shen, L.J., Hsu, L.F., et al. Pharmacokinetics of vancomycin in adults receiving extracorporeal membrane oxygenation. J Formos Med Assoc 115:7 (2016), 560–570.
44. 44 Cohen, P., Collart, L., Prober, C.G., et al. Gentamicin pharmacokinetics in neonates undergoing extracorporal membrane oxygenation. Pediatr Infect Dis J 9 (1990), 562–566.
45. 45 Southgate, W.M., DiPiro, J.T., Robertson, A.F., Pharmacokinetics of gentamicin in neonates on extracorporeal membrane oxygenation. Antimicrob Agents Chemother 33 (1989), 817–819.
46. 46 Munzenberger, P.J., Massoud, N., Pharmacokinetics of gentamicin in neonatal patients supported with extracorporeal membrane oxygenation. ASAIO Trans 37 (1991), 16–18.
47. 47 Kelman, A.W., Thomson, A.H., Whiting, B., et al. Estimation of gentamicin clearance and volume of distribution in neonates and young children. Br J Clin Pharmacol 18 (1984), 685–692.
48. 48 McDade, E.J., Wagner, J.L., Moffett, B.S., et al. Once-daily gentamicin dosing in pediatric patients without cystic fibrosis. Pharmacotherapy 30 (2010), 248–253.
49. 49 Ahsman, M.J., Wildschut, E.D., Tibboel, D., et al. Pharmacokinetics of cefotaxime and desacetylcefotaxime in infants during extracorporeal membrane oxygenation. Antimicrob Agents Chemother 54 (2010), 1734–1741.
50. 50 Lexicomp Online, Pediatric and Neonatal Lexi-Drugs. April 2016, Lexi-Comp, Inc, Hudson, Ohio.
51. 51 Cies, J.J., Moore, W.S. 2nd, Dickerman, M.J., et al. Pharmacokinetics of continuous-infusion meropenem in a pediatric patient receiving extracorporeal life support. Pharmacotherapy 34 (2014), e175–e179.
52. 52 Donadello, K., Antonucci, E., Cristallini, S., et al. beta-Lactam pharmacokinetics during extracorporeal membrane oxygenation therapy: A case-control study. Int J Antimicrob Agents 45 (2015), 278–282.
53. 53 Shekar, K., Fraser, J.F., Taccone, F.S., et al. The combined effects of extracorporeal membrane oxygenation and renal replacement therapy on meropenem pharmacokinetics: a matched cohort study. Crit Care, 18, 2014, 565.
54. 54 Bradley, J.S., Sauberan, J.B., Ambrose, P.G., et al. Meropenem pharmacokinetics, pharmacodynamics, and Monte Carlo simulation in the neonate. Pediatr Infect Dis J 27 (2008), 794–799.
55. 55 Smith, P.B., Cohen-Wolkowiez, M., Castro, L.M., et al. Population pharmacokinetics of meropenem in plasma and cerebrospinal fluid of infants with suspected or complicated intra-abdominal infections. Pediatr Infect Dis J 30 (2011), 844–849.
56. 56 Du, X., Li, C., Kuti, J.L., et al. Population pharmacokinetics and pharmacodynamics of meropenem in pediatric patients. J Clin Pharmacol 46 (2006), 69–75.
57. 57 Ohata, Y., Tomita, Y., Nakayama, M., et al. Optimal dosage regimen of meropenem for pediatric patients based on pharmacokinetic/pharmacodynamic considerations. Drug Metab Pharmacokinet 26 (2011), 523–531.
58. 58 Lexicomp Online, Lexi-Drugs. April 2016, LexiComp, Inc, Hudson, Ohio.
59. 59 Welsch, C., Augustin, P., Allyn, J., et al. Alveolar and serum concentrations of imipenem in two lung transplant recipients supported with extracorporeal membrane oxygenation. Transpl Infect Dis 17 (2015), 103–105.
60. 60 McKinnon, P.S., Paladino, J.A., Schentag, J.J., Evaluation of area under the inhibitory curve (AUIC) and time above the minimum inhibitory concentration (T>MIC) as predictors of outcome for cefepime and ceftazidime in serious bacterial infections. Int J Antimicrob Agents 31 (2008), 345–351.
61. 61 De Rosa, F.G., Corcione, S., Baietto, L., et al. Pharmacokinetics of linezolid during extracorporeal membrane oxygenation. Int J Antimicrob Agents 41 (2013), 590–591.
62. 62 Turner, R.B., Rouse, S., Elbarbry, F., et al. Azithromycin Pharmacokinetics in Adults With Acute Respiratory Distress Syndrome Undergoing Treatment With Extracorporeal-Membrane Oxygenation. Ann Pharmacother 50:1 (2016), 72–73.
63. 63 Veinstein, A., Debouverie, O., Gregoire, N., et al. Lack of effect of extracorporeal membrane oxygenation on tigecycline pharmacokinetics. J Antimicrob Chemother 67 (2012), 1047–1048.
64. 64 Kim, H.S., Lee, E.S., Cho, Y.J., Insufficient serum levels of antituberculosis agents during venovenous extracorporeal membrane oxygenation therapy for acute respiratory distress syndrome in a patient with miliary tuberculosis. ASAIO J 60 (2014), 484–486.
65. 65 Strunk, A.K., Ciesek, S., Schmidt, J.J., et al. Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment. Int J Infect Dis 42 (2016), 1–3.
66. 66 Gardner, A.H., Prodhan, P., Stovall, S.H., et al. Fungal infections and antifungal prophylaxis in pediatric cardiac extracorporeal life support. J Thorac Cardiovasc Surg 143:3 (2012), 689–695.
67. 67 Eppes, S.C., Troutman, J.L., Gutman, L.T., Outcome of treatment of candidemia in children whose central catheters were removed or retained. Pediatr Infect Dis J 8 (1989), 99–104.
68. 68 Watt, K.M., Benjamin, D.K. Jr., Cheifetz, I.M., et al. Pharmacokinetics and safety of fluconazole in young infants supported with extracorporeal membrane oxygenation. Pediatr Infect Dis J 31 (2012), 1042–1047.
69. 69 Watt, K.M., Gonzalez, D., Benjamin, D.K. Jr., et al. Fluconazole population pharmacokinetics and dosing for prevention and treatment of invasive Candidiasis in children supported with extracorporeal membrane oxygenation. Antimicrob Agents Chemother 59 (2015), 3935–3943.
70. 70 Autmizguine, J., Hornik, C.P., Benjamin, D.K. Jr., et al. Pharmacokinetics and Safety of Micafungin in Infants Supported with Extracorporeal Membrane Oxygenation. Pediatr Infect Dis J, 2016 Jun 16 [Epub ahead of print].
71. 71 Kuse, E.R., Chetchotisakd, P., da Cunha, C.A., et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369 (2007), 1519–1527.
72. 72 Smith, P.B., Walsh, T.J., Hope, W., et al. Pharmacokinetics of an elevated dosage of micafungin in premature neonates. Pediatr Infect Dis J 28 (2009), 412–415.
73. 73 Koch, B.C., Wildschut, E.D., Goede, A.L., et al. Insufficient serum caspofungin levels in a paediatric patient on ECMO. Med Mycol Case Rep 2 (2012), 23–24.
74. 74 Ruiz, S., Papy, E., Da Silva, D., et al. Potential voriconazole and caspofungin sequestration during extracorporeal membrane oxygenation. Intensive Care Med 35 (2009), 183–184.
75. 75 Spriet, I., Annaert, P., Meersseman, P., et al. Pharmacokinetics of caspofungin and voriconazole in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother 63 (2009), 767–770.
76. 76 Bruggemann, R.J., Antonius, T., Heijst, A., et al. Therapeutic drug monitoring of voriconazole in a child with invasive aspergillosis requiring extracorporeal membrane oxygenation. Ther Drug Monit 30 (2008), 643–646.
77. 77 Hertzog JH, B.E., Sale, M., Hauser, G.J., et al. Amphotericin B Pharmacokinetics During Extracorporeal Membrane Oxygenation: A Case Report. J Extra Corpor Technol 28 (1996), 94–98.
78. 78 Wildschut, E.D., de Hoog, M., Ahsman, M.J., et al. Plasma concentrations of oseltamivir and oseltamivir carboxylate in critically ill children on extracorporeal membrane oxygenation support. PLoS One, 5, 2010, e10938.
79. 79 Eyler, R.F., Heung, M., Pleva, M., et al. Pharmacokinetics of oseltamivir and oseltamivir carboxylate in critically ill patients receiving continuous venovenous hemodialysis and/or extracorporeal membrane oxygenation. Pharmacotherapy 32 (2012), 1061–1069.
80. 80 Lemaitre, F., Luyt, C.E., Roullet-Renoleau, F., et al. Impact of extracorporeal membrane oxygenation and continuous venovenous hemodiafiltration on the pharmacokinetics of oseltamivir carboxylate in critically ill patients with pandemic (H1N1) influenza. Ther Drug Monit 34 (2012), 171–175.
81. 81 Mulla, H., Peek, G.J., Harvey, C., et al. Oseltamivir pharmacokinetics in critically ill adults receiving extracorporeal membrane oxygenation support. Anaesth Intensive Care 41 (2013), 66–73.
82. 82 Shetty, A.K., Ross, G.A., Pranikoff, T., et al. Oseltamivir-resistant 2009 H1N1 influenza pneumonia during therapy in a renal transplant recipient. Pediatr Transplant 16 (2012), E153–E157.
83. 83 Aebi, C., Headrick, C.L., McCracken, G.H., et al. Intravenous ribavirin therapy in a neonate with disseminated adenovirus infection undergoing extracorporeal membrane oxygenation: pharmacokinetics and clearance by hemofiltration. J Pediatr 130 (1997), 612–615.
84. 84 Hocker, J.R., Cook, L.N., Adams, G., et al. Ganciclovir therapy of congenital cytomegalovirus pneumonia. Pediatr Infect Dis J 9 (1990), 743–745.
85. 85 Whitley, R.J., Cloud, G., Gruber, W., et al. Ganciclovir treatment of symptomatic congenital cytomegalovirus infection: results of a phase II study. National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. J Infect Dis 175 (1997), 1080–1086.
86. 86 Shekar, K., Roberts, J.A., Smith, M.T., et al. The ECMO PK Project: an incremental research approach to advance understanding of the pharmacokinetic alterations and improve patient outcomes during extracorporeal membrane oxygenation. BMC Anesthesiol, 13, 2013, 7.